Status: Recruiting
WATCHMAN FLX Pro European Registry
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.
Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Boston Scientific CorporationUpdated: Jun 24, 2026Locations: 14Duration: 12 Months
Eligibility criteria
Subject is attempted to be treated with the WATCHMAN FLX™ Pro LAAC device. [+4]
Subject has a documented life expectancy of less than 12 months. [+6]